Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report

Inflammation and coagulation are considered to the development of Coronavirus disease 2019 (COVID-19)-related hypoxemia. However, this is still controversial, which brings challenges to clinical treatment. Here, we reviewed the levels of interleukin-6 (IL-6), coagulation indexes, and clinical manife...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xu Qiancheng, Wang Tao, Lu Weihua
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	covid-19 sars-cov-2 tocilizumab cytokine storm inflammation coagulation Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/b3dda005a6c1475fb8f32cbf7445c68a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b3dda005a6c1475fb8f32cbf7445c68a
record_format	dspace
spelling	oai:doaj.org-article:b3dda005a6c1475fb8f32cbf7445c68a2021-12-05T14:10:41ZTherapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report2391-541210.1515/biol-2021-0088https://doaj.org/article/b3dda005a6c1475fb8f32cbf7445c68a2021-08-01T00:00:00Zhttps://doi.org/10.1515/biol-2021-0088https://doaj.org/toc/2391-5412Inflammation and coagulation are considered to the development of Coronavirus disease 2019 (COVID-19)-related hypoxemia. However, this is still controversial, which brings challenges to clinical treatment. Here, we reviewed the levels of interleukin-6 (IL-6), coagulation indexes, and clinical manifestations of a patient with severe COVID-19 after Tocilizumab administration. In this case, the patient’s body temperature quickly dropped to normal after using Tocilizumab, while C reactive protein progressively decreased and stabilized at a lower level. However, IL-6 and D-dimers increased and were accompanied by a continuous decrease of the oxygenation index. After anticoagulant therapy with heparin, D-dimer decreased slowly, gradually improving the oxygenation index and disease remission. This case suggests that the formation of microthrombus might be the main reason for COVID-19-derived hypoxemia. However, the mechanism of hypoxemia and the role of Tocilizumab in COVID-19 need further research. Nevertheless, these findings might still assist medical workers in formulating timely treatment strategies for similar severe patients.Xu QianchengWang TaoLu WeihuaDe Gruyterarticlecovid-19sars-cov-2tocilizumabcytokine storminflammationcoagulationBiology (General)QH301-705.5ENOpen Life Sciences, Vol 16, Iss 1, Pp 809-814 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 sars-cov-2 tocilizumab cytokine storm inflammation coagulation Biology (General) QH301-705.5
spellingShingle	covid-19 sars-cov-2 tocilizumab cytokine storm inflammation coagulation Biology (General) QH301-705.5 Xu Qiancheng Wang Tao Lu Weihua Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
description	Inflammation and coagulation are considered to the development of Coronavirus disease 2019 (COVID-19)-related hypoxemia. However, this is still controversial, which brings challenges to clinical treatment. Here, we reviewed the levels of interleukin-6 (IL-6), coagulation indexes, and clinical manifestations of a patient with severe COVID-19 after Tocilizumab administration. In this case, the patient’s body temperature quickly dropped to normal after using Tocilizumab, while C reactive protein progressively decreased and stabilized at a lower level. However, IL-6 and D-dimers increased and were accompanied by a continuous decrease of the oxygenation index. After anticoagulant therapy with heparin, D-dimer decreased slowly, gradually improving the oxygenation index and disease remission. This case suggests that the formation of microthrombus might be the main reason for COVID-19-derived hypoxemia. However, the mechanism of hypoxemia and the role of Tocilizumab in COVID-19 need further research. Nevertheless, these findings might still assist medical workers in formulating timely treatment strategies for similar severe patients.
format	article
author	Xu Qiancheng Wang Tao Lu Weihua
author_facet	Xu Qiancheng Wang Tao Lu Weihua
author_sort	Xu Qiancheng
title	Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
title_short	Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
title_full	Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
title_fullStr	Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
title_full_unstemmed	Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
title_sort	therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of covid-19: a case report
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/b3dda005a6c1475fb8f32cbf7445c68a
work_keys_str_mv	AT xuqiancheng therapeuticpotentialofanticoagulanttherapyinassociationwithcytokinestorminhibitioninseverecasesofcovid19acasereport AT wangtao therapeuticpotentialofanticoagulanttherapyinassociationwithcytokinestorminhibitioninseverecasesofcovid19acasereport AT luweihua therapeuticpotentialofanticoagulanttherapyinassociationwithcytokinestorminhibitioninseverecasesofcovid19acasereport
_version_	1718371860938227712

Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report

Ejemplares similares